Dexcom (DXCM) HR chief granted 39,019 RSUs, 17,199 shares withheld for tax

Rhea-AI Filing Summary

Dexcom EVP and Chief HR Officer Sadie Stern received a grant of 39,019 restricted stock units (RSUs) of Common Stock on March 8, 2026. These RSUs are scheduled to vest in three equal annual installments from the grant date, with each RSU representing a right to receive one Dexcom share.

On the same date, 17,199 shares were withheld by the company at a price of $68.10 per share to cover tax obligations related to RSU settlement; this is explicitly described as not being a sale by Stern. Following these transactions, Stern directly holds 131,510 shares of Common Stock, including 77,603 unvested RSUs with various grants vesting through March 8, 2029.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stern Sadie

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief HR Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/08/2026		A		39,019(1)	A	$0	148,709	D
Common Stock	03/08/2026		F		17,199(2)	D	$68.1	131,510(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock.

2. Represents the number of shares required to be withheld by the Issuer to cover tax withholding and remittance obligations in connection with the net settlement of RSUs and does not represent a sale by the Reporting Person.

3. Included in this number are 77,603 unvested RSUs, 39,019 of which were granted on March 8, 2026 and shall vest through March 8, 2029, 19,948 of which were granted on March 8, 2025 and shall vest through March 8, 2028, 11,399 of which were granted on March 8, 2025 and shall vest through March 8, 2027, and 7,237 of which were granted on March 8, 2024 and shall vest through March 8, 2027.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Sadie Stern	03/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Dexcom (DXCM) executive Sadie Stern report in this Form 4?

Sadie Stern reported a grant of 39,019 restricted stock units and related tax-withholding share dispositions. These moves reflect routine equity compensation and associated tax handling, leaving her with 131,510 Dexcom Common Stock shares directly held after the reported transactions.

How many Dexcom (DXCM) RSUs were granted to Sadie Stern and how do they vest?

Sadie Stern received 39,019 restricted stock units that vest in three equal annual installments from March 8, 2026. Each RSU represents a contingent right to receive one share of Dexcom Common Stock upon vesting, aligning compensation with long-term company performance.

Why were 17,199 Dexcom (DXCM) shares withheld in Sadie Stern’s Form 4?

The 17,199 shares represent amounts withheld by Dexcom to cover tax withholding and remittance obligations from RSU settlement. The filing states this does not represent a sale by Sadie Stern, but a mechanism to satisfy required tax liabilities on the equity award.

What is Sadie Stern’s Dexcom (DXCM) shareholding after these transactions?

After the reported RSU grant and tax withholding, Sadie Stern holds 131,510 Dexcom Common Stock shares directly. This figure includes 77,603 unvested RSUs from multiple grant dates, with vesting schedules extending through March 8, 2029, supporting ongoing long-term equity exposure.

How many unvested Dexcom (DXCM) RSUs does Sadie Stern have and what are their schedules?

Sadie Stern has 77,603 unvested RSUs, including 39,019 granted March 8, 2026 vesting through March 8, 2029. Additional tranches were granted March 8, 2025 and March 8, 2024, with vesting dates running through March 8, 2028 and March 8, 2027 respectively.